Sign In | Join Free | My frbiz.com
China Henan Lantian Medical Supplies Co.,Ltd. logo
Henan Lantian Medical Supplies Co.,Ltd.
The company always adheres to the core concept of "fast and accurate, live up to life", and is committed to providing excellent products and services for the society and contributing to the cause of
Verified Supplier

1 Years

Home > Ag Rapid Test Kit >

Coronavirus 2019-NCoV Ag Saliva Test Kit Rapid Sputum Test Kit

Henan Lantian Medical Supplies Co.,Ltd.
Trust Seal
Verified Supplier
Credit Check
Supplier Assessment

Coronavirus 2019-NCoV Ag Saliva Test Kit Rapid Sputum Test Kit

  • 1
  • 2

Brand Name : ZOSBIO

Model Number : 2019-NCoV Neutralizing Antibody

Certification : CE BfArm

Place of Origin : Henan,China

MOQ : To be negotiated

Price : To be negotiated

Supply Ability : 10000 Kit/Kit per Day

Delivery Time : To be negotiated

Packaging Details : Kit

Product name : 2019-NCoV Ag Saliva/Sputum Rapid Test (Immunochromatography) Usage Manual

Composition : Detection card, sample buffer

Storage conditions : 2℃~30℃

term of validity : 18 months

Expiration date : See label for details

Contact Now

2019-NCoV Ag Saliva/Sputum Rapid Test (Immunochromatography) Usage Manual

Intended Use


The kit is used for qualitative detection of 2019 ncov Ag collected from human saliva / sputum samples.
2019-ncov is a new type of β- COV. It can cause viral pneumonia. The main clinical manifestations are fever, fatigue, dry cough and so on. A few patients have nasal congestion, runny nose, sore throat, diarrhea and other symptoms. Critical cases often develop dyspnea and / or hypoxemia after one week. Severe cases quickly progress to acute respiratory distress syndrome, septic shock, uncorrectable metabolic acidosis and coagulation dysfunction.
This product uses side flow immunoassay to qualitatively detect 2019 ncov Ag in saliva / sputum samples of suspected patients. In the acute phase of infection, antigens are usually detected in saliva / sputum samples. Positive results indicate the presence of viral antigens, but the clinical relevance of patient history and other diagnostic information is also a necessary condition for determining the status of infection. Positive results cannot exclude bacterial infection or co infection with other viruses. The detected pathogen may not be the exact cause of the disease. Negative results cannot exclude 2019 ncov infection and should not only be used as a basis for treatment or patient management decisions (including infection control decisions). If the result is negative, the final decision shall be made in combination with the patient's recent contact history, medical history and whether there are clinical signs and symptoms consistent with 2019 ncov, and nucleic acid analysis shall be conducted for confirmation if necessary.

Principle of Detection


This kit is an immunoassay based on the principle of double antibody sandwich technology. As an indicator marker, the labeled 2019 ncov monoclonal antibody was sprayed on the binding pad. During the test, 2019 ncov Ag in the sample combined with labeled 2019 ncov monoclonal antibody to form Ag AB complex. This complex migrates upward on the membrane through capillary effect until it is captured by another 2019 ncov monoclonal antibody pre coated on the test line to form a sandwich complex. If 2019 ncov AG is present in the sample, a red band appears in the T area of the interpretation window. Otherwise, this is a negative result. The control line (c) is used for program control and should always be displayed if the test program is executed correctly.

Main Components


The kit consists of test card, sample buffer and swab.
Test card: it is composed of aluminum foil bag, desiccant, test strip and plastic card. The test strip is composed of absorbent paper, nitrocellulose film, sample pad, adhesive pad and rubber sheet. Nitrocellulose membrane t line (test line) is coated with 2019-ncov AB, C line (quality control line) is coated with Goat anti mouse polyclonal AB, and the binding pad contains labeled 2019-ncov ab.
Sample buffer: phosphate, sodium azide, etc.

Storage Conditions and Validity


Keep it at 2 ℃ ~ 30 ℃, and the validity period is tentatively 18 months.
The validity period of aluminum foil bag is one hour after unpacking.
Production batch number: see the label for details.
Validity period: see the label for details.

Sample Requirements


(1) Saliva sample collection: do not eat or drink water, including chewing gum or use tobacco products 30 minutes before saliva sample collection. Put the tip of the tongue against the upper jaw and collect saliva at the root of the tongue. Place the sterile disposable cotton swab under the root of the tongue for at least 10 seconds, completely immerse it in saliva and rotate it more than 5 times. (see Figure 1)
Note: false negative results may occur if saliva samples are not collected properly.

Figure 1 Methodsfor saliva sample collection

Figure 2 Methods for sputum sample collection

(2) Sputum specimen collection: after washing with clean water, cough up sputum forcefully, put it into the specimen bag, and wipe the specimen with a disposable sterile cotton swab. (see Figure 2)
(3) Sample treatment: the collected samples shall be treated with the sample buffer provided by this kit as soon as possible (if they cannot be treated immediately, the samples shall be stored in dry, sterilized and strictly sealed containers) for future inspection. 2 ℃ ~ 8 ℃ shall not exceed 24h, and - 70 ℃ shall be stored for a long time (but repeated freezing and thawing shall be avoided).

Test Method


Please read the instructions carefully before testing. Please put all reagents back to room temperature before the test. The test shall be carried out at room temperature.
1. Sample processing (see Figure 3)
(1) Insert the sampling swab into the sample buffer and rotate it close to the inner wall for about 10 times to make the sample dissolve in the solution as much as possible.
(2) Squeeze the tip of the swab along the inner wall of the tube to make the liquid flow into the tube as much as possible, and take out and discard the swab.
(3) Cover the dripper.

Figure 3 Sample processing

Figure 4 Test procedure

2. Test procedure (see Figure 4)
(1) Remove the test card.
(2) Extract 2 drops (about 80%) of the treated sample μ 50) Add it to the sampling hole of the test card, and then start the timer.
(3) Place the card at room temperature for 15 minutes to read the results. The result is invalid after 20 minutes.

Interpretation of Test Results


Interpretation of test card (see Figure 5):
1. Invalid result: the quality control line (line C) has no response, and the line is invalid, so it needs to be retested.
2. Negative results: quality control line (line C), red ribbon, coloring.
3. Positive results: the two red bands of test line (t line) and quality control line (C line) are colored.

Figure 5 Interpretation of test results

Limitation of Test Method


1. This product is a qualitative test and is only used for in vitro auxiliary diagnosis.
2. This product is suitable for saliva and sputum samples. Other sample types may have inaccurate or invalid results.
3. If there is no sputum sample from the patient, a nasopharyngeal swab sample should be used for testing.
4. Ensure that an appropriate amount of sample is added for testing. Too much or too little sample may lead to inaccurate results.
5. The test results of this reagent are only for clinical reference and should not be used as the only basis for clinical diagnosis and treatment. The final diagnosis of the disease should be made after a comprehensive evaluation of all clinical and laboratory results.

Product Performance Indicators


1. Detection limit: the inactivated sars-cov-2 virus culture was used in this study, and the minimum detection limit of the kit was 6 × 102TCID50/mL.
2. The enterprise reference material is used for testing, and the results shall meet the requirements of the enterprise reference material.
2.1 qualification rate of positive control samples: p1-p5 of the enterprise's positive control samples were tested as positive.
2.2 qualification rate of negative control samples: the negative control samples n1-n10 of the enterprise were tested as negative.
2.3 detection limit: the minimum detection limit of the testing enterprise is L1-L3, L1 is negative, L2 and L3 are positive.
2.4 reproducibility: the repeated reference materials J1 and J2 of the enterprise were detected, and they were positive for 10 times each.
3. Cross reaction: add the following concentrations of microorganisms and viruses to the sample according to the specified concentration to evaluate their potential interference to the 2019 ncov Ag test project. The results showed that there was no cross reaction and was not disturbed by various microorganisms and viruses.

SN Microorganisms Concentration Cross reaction
1 Coronavirus (HKU1, OC43, NL63 and 229E) 1.0×105TCID50/mL No
2 Influenza A H1N1 (novel influenza A H1N1 virus (2009), seasonal H1N1 influenza virus), H3N2, H5N1, H7N9 1.0×105TCID50/mL No
3 Influenza B (Yamagata strain, Victoria strain) 2.5×105TCID50/mL No
4 Respiratory syncytial virus 2.8×105TCID50/mL No
5 Group A, B, C of rhinovirus 2.0×105TCID50/mL No
6 Type 1, 2, 3, 4, 5, 7, 55 of adenovirus 2.0×105TCID50/mL No
7 Group A, B, C and D of enterovirus 2.0×105TCID50/mL No
8 EB virus 2.0×105TCID50/mL No
9 Measles virus 2.0×105TCID50/mL No
10 Human cytomegalovirus 2.0×105TCID50/mL No
11 Rotavirus 2.0×105TCID50/mL No
12 Norovirus 2.0×105TCID50/mL No
13 Mumps virus 2.0×105TCID50/mL No
14 Varicella-zoster virus 2.0×105TCID50/mL No
15 Mycoplasma pneumoniae 1.0×106CFU/mL No
16 Legionella pneumophila 1.0×106CFU/mL No
17 Haemophilus influenzae 1.0×106CFU/mL No
18 Streptococcus pyogenes (group A) 1.0×106CFU/mL No
19 Streptococcus pneumoniae 1.0×106CFU/mL No
20 Escherichia Coli 1.0×106CFU/mL No
21 Pseudomonas aeruginosa 1.0×106CFU/mL No
22 Neisseria meningitidis 1.0×106CFU/mL No
23 Candida albicans 1.0×106CFU/mL No
24 Staphylococcus aureus 1.0×106CFU/mL No

4. Interfering substances: The following concentrations of drugs were added to the samples at the specified concentrations to evaluate their potential interference in 2019-nCoV Ag test project. The results showed that all kinds of drugs did not interfere with the test results of this reagent.

Interfering substances Concentration Interfering substances Concentration
Mucoprotein 1mg/mL Ribavirin 0.4mg/mL
Whole Blood 1% Fluticasone 0.5mg/mL
Oxymetazoline 10mg/mL Dexamethasone 5 mg/mL
Histamine hydrochloride 10mg/mL Triamcinolone acetonide 5 mg/mL
Tobramycin 1mg/mL Levofloxacin 0.2 mg/mL
Oseltamivir 1mg/mL Azithromycin 0.1 mg/mL
Zanamivir 1mg/mL Ceftriaxone 0.4 mg/mL
Arbidol 0.5mg/mL Meropenem 0.2 mg/mL

5. Hook effect: detect 1.0 with inactivated 2019 ncov culture × No hook effect was observed in the high concentration range of 106tcid50 / ml.
The kit is used for qualitative detection of 2019 ncov Ag collected from human saliva / sputum samples.
2019 ncov is a new type of β- COV. Can cause viral pneumonia. The main clinical manifestations were fever, fatigue, dry cough and so on. A few patients have nasal congestion, runny nose, sore throat, diarrhea and other symptoms. Critical cases usually develop dyspnea and / or hypoxemia after one week. Severe cases will rapidly develop into acute respiratory distress syndrome, septic shock, uncorrectable metabolic acidosis and coagulation dysfunction.
This product uses side flow immunoassay to detect 2019 ncov Ag in saliva / sputum samples of suspected patients. In the acute phase of infection, antigens are usually detected in saliva / sputum samples. Positive results indicate the presence of viral antigens, but the clinical relevance of patient history and other diagnostic information is also a necessary condition for determining the status of infection. Positive results cannot exclude bacterial infection or co infection with other viruses. The detected pathogen may not be the exact cause of the disease. Negative results cannot exclude ncov infection in 2019 and should not be used only as a basis for treatment or patient management decisions (including infection control decisions). If the result is negative, the final decision will be made according to the recent contact history and history of the patient and whether there are clinical signs and symptoms consistent with the 2019 New Coronavirus.


6. Clinical study: RT-PCR detection reagent was used as comparison reagent to evaluate saliva and sputum samples respectively. 120 positive samples and 120 negative samples (RT-PCR) were selected for each sample size and detected with Zhongxiu reagent. The results are summarized as follows:

Precautions


1. This product is only used for in vitro diagnosis.
2. This product is disposable and cannot be recycled.
3. Read the instructions carefully before operation and carry out the experimental operation in strict accordance with the reagent instructions.
4. Avoid experiments under harsh environmental conditions (including 84 disinfectant, sodium hypochlorite, acid-base, acetaldehyde and other corrosive gases with high concentration, dust and other environments). After the experiment, the laboratory should be disinfected.
5. All samples and used reagents shall be regarded as potentially infectious substances and treated in accordance with local regulations.
6. The reagent shall be used within the validity period marked on the outer package. The test card shall be used as soon as possible after being taken out of the aluminum foil bag to prevent moisture.

Logo interpretation


Do not re-use

Store at 2℃~30℃

Consult instructions for use

In vitro diagnostic medical

device

Batch code

Use-by date
Keep dry

Keep away from sunlight

Authorized representative in the

European Community

Manufacturer

Basic Information


ZHONGXIU SCIENCE AND TECHNOLOGY CO.,LTD

Dingluan industrial zone ,Changyuan City,453400,P.R.CHINA

Tel:+86-371-55016575

Email:zosbio@zosbio.com

Web:www.zosbio.com

SUNGO Europe B.V.

Olympisch Stadion 24, 1076DE Amsterdam, Netherlands

Company profile


Zhongxiu Science And Technology Co.,Ltd., is a high-tech enterprise engaged in the research and development, production and operation of in vitro diagnostic products. The in vitro diagnostic products developed by the company cover POCT series, microbial series, biochemical series and immune series reagents and supporting instruments.
The company has always adhered to the core concept of "fast and accurate, living up to life", committed to providing society with excellent products and services, and contributing to the cause of human health.

5 mg/mL

Product Tags:

2019-NCoV Ag Saliva Test Kit

      

Coronavirus Ag Saliva Test Kit

      

2019-NCoV Rapid Sputum Test Kit

      
China Coronavirus 2019-NCoV Ag Saliva Test Kit Rapid Sputum Test Kit wholesale

Coronavirus 2019-NCoV Ag Saliva Test Kit Rapid Sputum Test Kit Images

Inquiry Cart 0
Send your message to this supplier
 
*From:
*To: Henan Lantian Medical Supplies Co.,Ltd.
*Subject:
*Message:
Characters Remaining: (0/3000)
 

Home| Products| Suppliers| Quality Suppliers| Site Map |About Us |Contact Us |Help |关于我们 |联系我们

Copyright © 2009 - 2021 frbiz.com. All rights reserved.